STOCK TITAN

Cellectis - CLLS STOCK NEWS

Welcome to our dedicated page for Cellectis news (Ticker: CLLS), a resource for investors and traders seeking the latest updates and insights on Cellectis stock.

About Cellectis

Cellectis (NASDAQ: CLLS) is a clinical-stage biopharmaceutical company at the forefront of gene-editing technologies, dedicated to developing innovative cancer immunotherapies and other therapeutic solutions. Leveraging over 18 years of expertise in genome engineering, Cellectis has established itself as a pioneer in the field, utilizing its proprietary TALEN® (Transcription Activator-Like Effector Nucleases) technology and PulseAgile electroporation system to create precise, next-generation therapies. These tools enable the company to harness the immune system's power to target and eliminate cancer cells effectively.

Core Focus: Allogeneic CAR-T and Gene-Edited HSPCs

Cellectis specializes in developing allogeneic Chimeric Antigen Receptor T-cells (UCART) for immuno-oncology applications. Unlike traditional autologous CAR-T therapies, which require harvesting and engineering a patient’s own cells, Cellectis’s allogeneic approach uses gene-edited donor cells. This innovation offers scalability, reduced manufacturing costs, and faster availability, making it a game-changer in cancer treatment. Additionally, the company is advancing gene-edited hematopoietic stem and progenitor cells (HSPCs) for therapeutic indications beyond oncology, showcasing its versatility in genome editing.

Proprietary Technologies

Cellectis’s competitive edge lies in its proprietary technologies:

  • TALEN® Technology: A precise and versatile gene-editing tool that enables targeted modifications to DNA, ensuring high specificity and minimal off-target effects.
  • PulseAgile Electroporation System: A cutting-edge delivery platform that enhances the efficiency of introducing genetic material into cells.

These technologies form the backbone of Cellectis’s product pipeline, enabling the development of innovative therapies that address unmet medical needs.

Market Position and Industry Context

Cellectis operates within the rapidly growing fields of immuno-oncology and precision medicine. The global demand for effective cancer therapies continues to rise, driven by advancements in biotechnology and an increasing understanding of the immune system's role in combating diseases. As a clinical-stage company, Cellectis focuses on research and development, with a pipeline of promising product candidates undergoing rigorous clinical trials. However, this stage also presents challenges, including regulatory approvals, high R&D costs, and competition from other biotech firms specializing in gene editing and CAR-T therapies.

Competitive Landscape

Key competitors in the gene-editing and CAR-T therapy space include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics. Cellectis differentiates itself through its allogeneic approach, which offers significant advantages in scalability and cost-effectiveness. By addressing the limitations of autologous therapies, such as manufacturing complexity and patient-specific variability, Cellectis positions itself as a leader in next-generation cancer immunotherapies.

Challenges and Opportunities

While Cellectis’s innovative approach holds immense promise, the company faces several challenges. These include navigating a complex regulatory environment, managing high development costs, and competing in a crowded market. However, the potential rewards are substantial, with successful therapies offering transformative benefits for patients and significant market opportunities. The company’s focus on leveraging proprietary technologies and addressing unmet medical needs positions it well for long-term success.

Conclusion

Cellectis is a trailblazer in the biopharmaceutical industry, combining cutting-edge gene-editing technologies with a commitment to innovation in cancer immunotherapy and beyond. By leveraging its proprietary TALEN® technology and allogeneic approach, the company aims to revolutionize the treatment landscape, offering scalable, cost-effective solutions to some of the most pressing medical challenges. As a clinical-stage entity, Cellectis represents a high-risk, high-reward opportunity within the dynamic biotechnology sector.

Rhea-AI Summary

Cellectis (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company specializing in gene-editing platform technologies, will announce its first quarter 2024 financial results on May 28, 2024, after the US market closes. The results will cover the period ending March 31, 2024. Following the announcement, the Company will hold an investor conference call and webcast on May 29, 2024, at 8:00 AM ET / 2:00 PM CET to discuss the financial results and provide an update on business activities. Investors and stakeholders can join the call using the provided domestic and international dial-in numbers or access the webcast online.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.42%
Tags
conferences earnings
-
Rhea-AI Summary

On May 16, 2024, Cellectis released its monthly update on share capital and voting rights as stipulated by Article 223-16 of the French financial markets authority. The company, listed on Euronext Growth under the ISIN code FR0010425595, reported a total of 99,955,535 shares in its capital and 87,891,239 voting rights as of May 3, 2024. For more details, the company provided contact information for their media and investor relations teams.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.64%
Tags
none
-
Rhea-AI Summary

In a recent press release, Cellectis provided information on their share capital and company voting rights for April 30, 2024. The total number of shares in the capital was reported as 71,955,535 with a total number of voting rights at 77,891,229. This data was disclosed in compliance with Article 223-16 of the General Regulation of the French financial markets authority.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.46%
Tags
none
Rhea-AI Summary

Cellectis announced the completion of an additional equity investment of $140M by AstraZeneca. AstraZeneca purchased 10,000,000 class A convertible preferred shares and 18,000,000 class B convertible preferred shares at $5.00 per share. This move solidifies AstraZeneca's ownership in Cellectis, giving them approximately 44% of the share capital and 30% of the voting rights in the company.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.04%
Tags
none
-
Rhea-AI Summary

Cellectis appointed Arthur Stril as the interim Chief Financial Officer, replacing Bing Wang. Mr. Stril, with a strong background in finance and business development, will oversee finance, investor relations, and business development functions. His appointment comes at a critical growth phase for Cellectis, as they advance their pipeline of assets and explore new opportunities.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
management
-
Rhea-AI Summary

Cellectis reported financial results for the fourth quarter and full year 2023, highlighting key events like clinical study updates, strategic collaborations with AstraZeneca, and cash position. The company remains focused on advancing its Phase 1 clinical trials, presenting promising data on UCART22 and UCART20x22 at the ASH conference. The collaboration with AstraZeneca aims to develop innovative cell and gene therapies. Financially, Cellectis saw a significant increase in cash position to $156 million as of December 31, 2023.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
Rhea-AI Summary
Cellectis presents novel TALEN editing processes enabling highly efficient gene correction and gene insertion in HSPCs, showcasing the potential and versatility of the technology for gene therapy. The company will present first data exploring these processes at ASGCT. The editing approaches could revolutionize the treatment of metabolic and neurological diseases, allowing for lineage-specific expression of therapeutics and efficient gene insertion without compromising cell viability.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.76%
Tags
none
-
Rhea-AI Summary
Cellectis (NASDAQ: CLLS) announces a breakthrough in gene-editing therapy with the publication of a new research paper. The study demonstrates the potential of TALEN-mediated intron editing in HSPCs for targeted transgene expression, offering new treatment possibilities for metabolic and neurological diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.36%
Tags
none
-
Rhea-AI Summary
Cellectis, a biotechnology company, announced the presentation of preliminary data on a novel TALEN® gene-editing process for hematopoietic stem cells at the ASGCT 27th Annual Meeting. The company showcased improvements in gene correction and insertion in HSPCs, along with a strategy for lineage-specific expression of therapeutics.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.23%
Tags
none
Rhea-AI Summary
Cellectis announces voting rights for March 2024 with a total of 77,889,229 voting rights from 71,953,535 shares in the capital, listed on Euronext Growth with ISIN code FR0010425595.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.55%
Tags
none

FAQ

What is the current stock price of Cellectis (CLLS)?

The current stock price of Cellectis (CLLS) is $1.32 as of April 1, 2025.

What is the market cap of Cellectis (CLLS)?

The market cap of Cellectis (CLLS) is approximately 131.1M.

What does Cellectis specialize in?

Cellectis specializes in developing gene-edited cancer immunotherapies, particularly allogeneic CAR-T cells, and other therapeutic applications using its proprietary TALEN® technology.

How does Cellectis differentiate from competitors?

Cellectis focuses on allogeneic CAR-T therapies, which offer scalability and cost advantages over autologous approaches. Its proprietary TALEN® technology ensures precise gene editing.

What are Cellectis’s proprietary technologies?

Cellectis utilizes TALEN® for precise gene editing and the PulseAgile electroporation system for efficient genetic material delivery into cells.

What challenges does Cellectis face?

As a clinical-stage company, Cellectis faces challenges such as regulatory hurdles, high R&D costs, and competition from other biotech firms in the gene-editing and immunotherapy space.

What is the significance of allogeneic CAR-T therapies?

Allogeneic CAR-T therapies use gene-edited donor cells, providing scalability, reduced manufacturing costs, and faster availability compared to patient-specific autologous therapies.

What market does Cellectis target?

Cellectis targets the immuno-oncology market with its cancer immunotherapies and explores other therapeutic indications through gene-edited hematopoietic stem and progenitor cells.

Who are Cellectis’s main competitors?

Competitors include CRISPR Therapeutics, Editas Medicine, and Intellia Therapeutics, all of which focus on gene-editing technologies and related therapies.

What stage of development is Cellectis in?

Cellectis is a clinical-stage biopharmaceutical company, focusing on research, development, and clinical trials for its product candidates.
Cellectis

Nasdaq:CLLS

CLLS Rankings

CLLS Stock Data

131.12M
69.31M
3.87%
20.71%
0.24%
Biotechnology
Healthcare
Link
France
Paris